Gemcitabine controlled release (TARIS Biomedical)

N/A

Report date: 2025/11/07 15:50:47

Base Information

Drug NameGemcitabine controlled release (TARIS Biomedical)
Drug Alias NameGemcitabine-releasing intravesical system (TARIS Biomedical)GemRISRIS/gemcitabineJNJ-17000139JNJ-17000139-AAC +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA inhibitors
TargetsRibonucleotide reductaseDNA
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsUrinary Bladder Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/09/09
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca PlcTaris Biomedical Llc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Biotech IncJanssen Research & Development Llc
Inactive CompaniesJohnson & Johnson
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A